BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Makri E, Cholongitas E, Tziomalos K. Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease. World J Gastroenterol 2016; 22(41): 9039-9043 [PMID: 27895393 DOI: 10.3748/wjg.v22.i41.9039]
URL: https://www.wjgnet.com/1948-5182/full/v22/i41/9039.htm
Number Citing Articles
1
Xiao Yang, Frank J. Gonzalez, Min Huang, Huichang Bi. Nuclear receptors and non-alcoholic fatty liver disease: An updateLiver Research 2020; 4(2): 88 doi: 10.1016/j.livres.2020.03.001
2
Simona Cernea, Avivit Cahn, Itamar Raz. Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetesExpert Review of Clinical Pharmacology 2017; 10(5): 535 doi: 10.1080/17512433.2017.1300059
3
Marc S. Rendell. Current and emerging gluconeogenesis inhibitors for the treatment of Type 2 diabetesExpert Opinion on Pharmacotherapy 2021; 22(16): 2167 doi: 10.1080/14656566.2021.1958779
4
Vik Meadows, Lindsey Kennedy, Debjyoti Kundu, Gianfranco Alpini, Heather Francis. Bile Acid Receptor Therapeutics Effects on Chronic Liver DiseasesFrontiers in Medicine 2020; 7 doi: 10.3389/fmed.2020.00015
5
Maria Vasco, Rossella Paolillo, Concetta Schiano, Linda Sommese, Oreste Cuomo, Claudio Napoli. Compromised nutritional status in patients with end-stage liver disease: Role of gut microbiotaHepatobiliary & Pancreatic Diseases International 2018; 17(4): 290 doi: 10.1016/j.hbpd.2018.06.004
6
Maria Ryaboshapkina, Mårten Hammar. Human hepatic gene expression signature of non-alcoholic fatty liver disease progression, a meta-analysisScientific Reports 2017; 7(1) doi: 10.1038/s41598-017-10930-w
7
Hongkui Wu, Gang Liu, Yaoli He, Jing Da, Bingqing Xie. Obeticholic acid protects against diabetic cardiomyopathy by activation of FXR/Nrf2 signaling in db/db miceEuropean Journal of Pharmacology 2019; 858: 172393 doi: 10.1016/j.ejphar.2019.05.022
8
Joseph M Pappachan, Shithu Babu, Babu Krishnan, Nishal C Ravindran. Non-alcoholic Fatty Liver Disease: A Clinical UpdateJournal of Clinical and Translational Hepatology 2017; (XX): XX doi: 10.14218/JCTH.2017.00013
9
Lucienne Juillerat-Jeanneret, John-David Aubert, Josip Mikulic, Dela Golshayan. Fibrogenic Disorders in Human Diseases: From Inflammation to Organ DysfunctionJournal of Medicinal Chemistry 2018; 61(22): 9811 doi: 10.1021/acs.jmedchem.8b00294
10
Michal Herman-Edelstein, Talia Weinstein, Moshe Levi. Bile acid receptors and the kidneyCurrent Opinion in Nephrology and Hypertension 2018; 27(1): 56 doi: 10.1097/MNH.0000000000000374
11
Ahmed Lotfy, Shimaa El-Metwaly, Reham Soliman, Ayman A. Hassan, Gamal Shiha. Umbilical Cord Mesenchymal Stem/Stromal Cells and Low-Dose Obeticholic Acid as a Possible Combined Treatment for Liver FibrosisStem Cell Reviews and Reports 2022;  doi: 10.1007/s12015-022-10346-8
12
Savinda Liyanagedera, Robert Patrick Williams, Silvio Veraldi, Valerio Nobili, Jake P. Mann. The pharmacological management of NAFLD in children and adolescentsExpert Review of Clinical Pharmacology 2017; 10(11): 1225 doi: 10.1080/17512433.2017.1365599
13
Giuseppina Palladini, Marta Cagna, Laura Giuseppina Di Pasqua, Luciano Adorini, Anna Cleta Croce, Stefano Perlini, Andrea Ferrigno, Clarissa Berardo, Mariapia Vairetti. Obeticholic Acid Reduces Kidney Matrix Metalloproteinase Activation Following Partial Hepatic Ischemia/Reperfusion Injury in RatsPharmaceuticals 2022; 15(5): 524 doi: 10.3390/ph15050524
14
Shentian Zhuang, Qiang Li, Lirong Cai, Chu Wang, Xiaoguang Lei. Chemoproteomic Profiling of Bile Acid Interacting ProteinsACS Central Science 2017; 3(5): 501 doi: 10.1021/acscentsci.7b00134
15
Vik Meadows, Lindsey Kennedy, Burcin Ekser, Konstantina Kyritsi, Debjyoti Kundu, Tianhao Zhou, Lixian Chen, Linh Pham, Nan Wu, Jennifer Demieville, Laura Hargrove, Shannon Glaser, Gianfranco Alpini, Heather Francis. Mast Cells Regulate Ductular Reaction and Intestinal Inflammation in Cholestasis Through Farnesoid X Receptor SignalingHepatology 2021; 74(5): 2684 doi: 10.1002/hep.32028
16
Michelle Ma, Katie Falloon, Po-Hung Chen, Behnam Saberi, Aliaksei Pustavoitau, Elif Ozdogan, Zhiping Li, Benjamin Philosophe, Andrew M. Cameron, Ahmet Gurakar. The Role of Liver Transplantation in Alcoholic HepatitisJournal of Intensive Care Medicine 2019; 34(4): 277 doi: 10.1177/0885066618780339
17
CS Gautam, Jatin Sharma, Mandeep Singla, Ilmjot Kaur Tiwana, Harmanjit Singh. Potential Role of Dexamphetamine in the Treatment of Non-alcoholic Fatty Liver Disease: Hopes and PitfallsEuropean Endocrinology 2021; 1(1): 33 doi: 10.17925/EE.2021.17.1.33
18
Vasilios G. Athyros, Theodore K. Alexandrides, Helen Bilianou, Evangelos Cholongitas, Michael Doumas, Emmanuel S. Ganotakis, John Goudevenos, Moses S. Elisaf, Georgios Germanidis, Olga Giouleme, Asterios Karagiannis, Charalambos Karvounis, Niki Katsiki, Vasilios Kotsis, Jannis Kountouras, Evangelos Liberopoulos, Christos Pitsavos, Stergios Polyzos, Loukianos S. Rallidis, Dimitrios Richter, Apostolos G. Tsapas, Alexandros D. Tselepis, Konstantinos Tsioufis, Konstantinos Tziomalos, Themistoklis Tzotzas, Themistoklis G. Vasiliadis, Charalambos Vlachopoulos, Dimitri P. Mikhailidis, Christos Mantzoros. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel StatementMetabolism 2017; 71: 17 doi: 10.1016/j.metabol.2017.02.014
19
Eunsol Choi, Eungyeong Jang, Jang-Hoon Lee. Pharmacological Activities of Alisma orientale against Nonalcoholic Fatty Liver Disease and Metabolic Syndrome: Literature ReviewEvidence-Based Complementary and Alternative Medicine 2019; 2019: 1 doi: 10.1155/2019/2943162
20
Sukhpreet Singh, Natalia A Osna, Kusum K Kharbanda. Treatment options for alcoholic and non-alcoholic fatty liver disease: A reviewWorld Journal of Gastroenterology 2017; 23(36): 6549-6570 doi: 10.3748/wjg.v23.i36.6549
21
Monjur Ahmed. Non-Alcoholic Fatty Liver Disease - Molecular Bases, Prevention and Treatment2018;  doi: 10.5772/intechopen.72000
22
CS Gautam, Jatin Sharma, Mandeep Singla, Ilmjot Kaur Tiwana, Harmanjit Singh. Potential Role of Dexamphetamine in the Treatment of Non-alcoholic Fatty Liver Disease: Hopes and PitfallsEuropean Endocrinology 2021; 1(1): 33 doi: 10.17925/EE.2021.1.1.33
23
S Singh, KK Kharbanda. Farnesoid X Receptor Agonist as a new treatment option for Non-Alcoholic Fatty Liver disease: A ReviewArchives of Hepatitis Research 2017; 3(1): 029 doi: 10.17352/ahr.000014
24
Eloy D. Hernandez, Lianxing Zheng, Young Kim, Bin Fang, Bo Liu, Reginald A. Valdez, William F. Dietrich, Paul V. Rucker, Donatella Chianelli, James Schmeits, Dingjiu Bao, Jocelyn Zoll, Claire Dubois, Glenn C. Federe, Lihao Chen, Sean B. Joseph, Lloyd B. Klickstein, John Walker, Valentina Molteni, Peter McNamara, Shelly Meeusen, David C. Tully, Michael K. Badman, Jie Xu, Bryan Laffitte. Tropifexor‐Mediated Abrogation of Steatohepatitis and Fibrosis Is Associated With the Antioxidative Gene Expression Profile in RodentsHepatology Communications 2019; 3(8): 1085 doi: 10.1002/hep4.1368
25
Lin Zhuang, Wenbin Ding, Qi Zhang, Wei Ding, Xuezhong Xu, Xiaolong Yu, Dong Xi. TGR5 Attenuated Liver Ischemia-Reperfusion Injury by Activating the Keap1-Nrf2 Signaling Pathway in MiceInflammation 2021; 44(3): 859 doi: 10.1007/s10753-020-01382-y
26
Maryam Mahjoubin-Tehran, Antonio De Vincentis, Dimitri P. Mikhailidis, Stephen L. Atkin, Christos S. Mantzoros, Tannaz Jamialahmadi, Amirhossein Sahebkar. Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosisMolecular Metabolism 2021; 50: 101049 doi: 10.1016/j.molmet.2020.101049